Replies to post #76052 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

"but there has been too many opportunities for this company to shed light and they haven't"

They have! Regarding phase 3 results they have stated the trial is ongoing and moving towards completion. They cannot announce results until the trial is finished and results are processed. To "shed light" on other matters relating to the trial assumes they are in a position to do so, you simply do not know this. When you say they have plenty of opportunities what were they ? You cannot say because you do not know. As with other posters who are heavily underwater your post is filled with insecurity, fear and doubt. I cannot blame you for that as it is likely you stand to lose a lot of money but that is what you risked from the onset [as did we all]. Yes the trial might fail but what you are accusing them of is ridiculous and not even credible. linda and Les are not stupid and that is exactly what they would need to be to hide results until a time to suit in breach of regulations and the law, not even credible.

[bullrider2]

If this if your first post at lease under this alias name, and you have been following the company for years as an investor. Than While release your first post with a whole lotta of negative. Why shoot holes all into your investment. adam and the crew has already tried to do this. I'am the opposite, I believe Northwest is going to get approval for DCVax-L for the treatment of Brain Cancer.

NorthWest bio has open P3 clinical trial all over the world. Not only because they want to expand their DCVax clinical trial studies all over the world, but also to have medical professional fully trained in administrating the DCVax procedures correctly for patient care. Especially when the P3 clinical trial is completed and FDA approval. NorthWest Bio will have no need to wait until the last minute to start training medical staff how to administrate the therapeutics treatment for each patient in different parts of the world, because they will have the train medical staff professional before DCVax-L is made available commercialize.

IMO P3 continuing clinical trial study is mostly all about training future medical staff how to correctly administrate DCVax-L and the type of care for each patient. The FDA approval is in the bag.

[Goodtime13]

This would be the Smith on Stocks point of view. That regulators are allowing the trial to continue - even though it will most likely fail or has failed (via an Interim analysis) to gather valuable data.

Not sure I agree with this.

a. If it had failed why would NWBO continue to pay for the trial for over a year....

b. Not sure the FDA would allow this...

c. I can plausibly see there not being enough events yet....

d. 13 months after a screening hold is a long time....

What may be plausible is that an interim analysis showed a failure in PFS but NWBO is arguing that if the trial continues overall survival will prove significant and that in itself should make L approvable.

Who knows.....I am in the same situation as you PharmD